AbbVie's Q3 2026: Strong Performance and Bold Moves
A Deep Dive into AbbVie's Q3 2026 Numbers Bruised and battered from the ebbs and flows of the market, AbbVie (NYSE:ABBV) decided to show up in swagger mode for the third quarter of 2026. They doubled their diluted EPS year over year with a GAAP figure hitting $2.37, backed by an adjusted EPS of $3.82. You're seeing the fruits of savvy expansions and a portfolio that seems...
Continue Reading